Inventor
KING DAVID J
US39 patents
⚠️ This page may combine multiple inventors who share the name “KING DAVID J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ANAPTYSBIO INC
16 patentsUS9815897B2Nov 14, 2017
Antibodies directed against programmed death-1 (PD-1)
ANAPTYSBIO INC24 citations93
US9133269B2Sep 15, 2015
Humanized antibodies directed against complement protein C5
ANAPTYSBIO INC20 citations87
US10738117B2Aug 11, 2020
Antibodies directed against programmed death-1 (PD-1)
ANAPTYSBIO INC10 citations83
US10059764B2Aug 28, 2018
Antibodies directed against interleukin-33 (IL-33) and methods of making and using
ANAPTYSBIO INC6 citations82
US10526410B2Jan 7, 2020
Antibodies directed against interleukin 36 receptor (IL-36R)
ANAPTYSBIO INC7 citations81
US10508149B2Dec 17, 2019
Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
ANAPTYSBIO INC7 citations80
US10836820B2Nov 17, 2020
Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33)
ANAPTYSBIO INC1 citations71
US11130814B2Sep 28, 2021
Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R)
ANAPTYSBIO INC2 citations70
US11352427B2Jun 7, 2022
Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)
ANAPTYSBIO INC2 citations69
US11155624B2Oct 26, 2021
Antibodies directed against programmed death-1 (PD-1)
ANAPTYSBIO INC4 citations69
US11753472B2Sep 12, 2023
Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
ANAPTYSBIO INC2 citations65
US11999783B2Jun 4, 2024
Method of treating autoimmune disease with antibodies against IL-33
ANAPTYSBIO INC0 citations61
US12391761B2Aug 19, 2025
Antibodies directed against interleukin 36 receptor (IL-36R)
ANAPTYSBIO INC0 citations59
US10836824B2Nov 17, 2020
Antibodies directed against lymphocyte activation gene 3 (LAG-3)
ANAPTYSBIO INC1 citations59
US9951126B2Apr 24, 2018
Antibodies directed against nerve growth factor (NGF)
ANAPTYSBIO INC0 citations47
US8926978B2Jan 6, 2015
Antibodies directed against nerve growth factor (NGF)
ANAPTYSBIO INC0 citations47
MASTERCARD INTERNATIONAL INC
6 patentsUS9948467B2Apr 17, 2018
Method and system for blockchain variant using digital signatures
MASTERCARD INTERNATIONAL INC85 citations98
US10171248B2Jan 1, 2019
Method and system blockchain variant using digital signatures
MASTERCARD INTERNATIONAL INC23 citations94
US10417188B2Sep 17, 2019
Method and system for transferring trust across block chain segments
MASTERCARD INTERNATIONAL INC11 citations84
US10348484B2Jul 9, 2019
Method and system for fast tracking navigation of blockchains via data manipulation
MASTERCARD INTERNATIONAL INC7 citations84
US10880075B2Dec 29, 2020
Method and system for fast tracking navigation of blockchains via data manipulation
MASTERCARD INTERNATIONAL INC3 citations73
US10567175B2Feb 18, 2020
Method and system blockchain variant using digital signatures
MASTERCARD INTERNATIONAL INC0 citations52
MEDAREX INC
4 patentsUS7498302B2Mar 3, 2009
Disulfide prodrugs and linkers and stabilizers useful therefor
MEDAREX INC123 citations98
US6989452B2Jan 24, 2006
Disulfide prodrugs and linkers and stabilizers useful therefor
MEDAREX INC284 citations98
US7619070B2Nov 17, 2009
Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
MEDAREX INC8 citations83
US8025882B2Sep 27, 2011
Interferon alpha antibodies and their uses
MEDAREX INC4 citations72
MOMENTA PHARMACEUTICALS INC
3 patentsUS10676526B2Jun 9, 2020
FcRn antibodies and methods of use thereof
MOMENTA PHARMACEUTICALS INC9 citations82
US11345751B2May 31, 2022
FcRn antibodies and methods of use thereof
MOMENTA PHARMACEUTICALS INC4 citations70
US11732047B2Aug 22, 2023
FcRn antibodies and methods of use thereof
MOMENTA PHARMACEUTICALS INC1 citations61
UNIV TEXAS
2 patentsLASSEN THERAPEUTICS INC
2 patentsUS12365738B2Jul 22, 2025
Method of treating an interleukin-11-associated or -mediated fibrotic disease or condition by administering an anti-interleukin-11 receptor subunit alpha (IL-11RA) antibody
LASSEN THERAPEUTICS INC0 citations54
US12365737B2Jul 22, 2025
Anti-IL-18BP antibodies
LASSEN THERAPEUTICS INC0 citations33